NASDAQ: PMNPromis Neurosciences Inc Stock
$4.97+0.07 (+1.43%)
Updated Jun 9, 2023
PMN Price
$4.97
Fair Value Price
N/A
Market Cap
$42.64M
52 Week Low
$4.05
52 Week High
$9.80
P/E
-1.83x
P/B
-6.9x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.72
Operating Cash Flow
-$16M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PMN Overview
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PMN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PMN due diligence checks available for Premium users.
Be the first to know about important PMN news, forecast changes, insider trades & much more!
PMN News
Valuation
PMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.83x
Industry
11.33x
Market
52.94x
PMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.9x
Industry
5.2x
PMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.0M
Profit Margin
0%
PMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.4M
Liabilities
$10.6M
Debt to equity
-1.72
PMN's short-term liabilities ($8.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMN's short-term assets ($4.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$0.0
Financing
$0.0
PMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMN vs Biotech Stocks
Promis Neurosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.